脑膜瘤立体定向放射外科35年演变
该研究回顾1987年至2022年接受单次立体定向放射外科(SRS)的脑膜瘤患者(2220个肿瘤,女性1229例,占69.8%),随访至少6个月。结果显示5年、10年、15年、20年肿瘤控制率分别为92.1%、88.3%、84.1%、81.1%,中位总生存17.4年,2.6%患者死于脑膜瘤进展。初次SRS的肿瘤控制优于术后辅助SRS,且肿瘤≥60%体积接受至少16 Gy者控制显著更优。
要点
- SRS对脑膜瘤的局部控制可维持20年以上,20年控制率81.1%。
- 初次SRS的肿瘤控制优于先前切除后的辅助SRS。
- 肿瘤≥60%体积接受至少16 Gy者肿瘤控制显著更优。
核心结论
- SRS提供超过20年的优异局部肿瘤控制率。
- 初次SRS对未切除或已知WHO I级脑膜瘤是有效策略。
- 辅助SRS是切除后残留或进展肿瘤增强控制与生存的重要选择。
研究设计与样本
- 回顾性分析1987年8月至2022年3月接受单次SRS的脑膜瘤患者,共2220个肿瘤,女性1229例(69.8%),随访至少6个月。
主要发现
- 末次随访时191/2220例(8.6%)出现局部进展。
- 5年、10年、15年、20年肿瘤控制率分别为92.1%、88.3%、84.1%、81.1%。
- SRS后中位总生存17.4年,2.6%患者死于脑膜瘤进展。
关键数值与推荐
- 肿瘤≥60%体积接受至少16 Gy者肿瘤控制显著更优。
临床怎么用
- 对未切除或已知WHO I级脑膜瘤可优先考虑初次SRS。
- 对切除后残留或进展肿瘤,辅助SRS可增强肿瘤控制与生存。
- 规划SRS时确保肿瘤≥60%体积接受至少16 Gy以优化控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Since the introduction of the Leksell Gamma Knife to North America in 1987, stereotactic radiosurgery (SRS) has increasingly been used for patients with intracranial meningiomas. We evaluated the evolving application and outcomes of meningioma patients managed with both primary and adjuvant SRS during a 35-year interval. METHODS: The authors reviewed the outcomes of meningioma patients (1229 female, 69.8%; 2220 tumors) who underwent single-fraction SRS from August 1987 to March 2022 and who had a minimum of 6-month follow-up. The rates of treated tumor control and overall survival up to 20 years after SRS were measured. Risk factors analyzed included age, sex, tumor volume, margin dose, Ki-67, anatomical location, and pre-SRS surgical resection. RESULTS: Primary SRS showed superior tumor control compared with adjuvant SRS after previous resection. Overall, 191 of 2220 patients (8.6%) had local progression at last follow-up with the 5-year, 10-year, 15-year, and 20-year tumor control rates were 92.1%, 88.3%, 84.1%, and 81.1%, respectively. The median overall survival after SRS was 17.4 years, and 2.6% of patients died related to meningioma progression. Patients treated so that ≥60% of the tumor received at least 16 Gy demonstrated significantly superior tumor control. Fifty-eight patients (3.3%) experienced symptomatic adverse radiation effects after SRS. CONCLUSION: SRS provided excellent local tumor control rates that extended beyond 20 years. Primary SRS was an effective strategy for patients with unresected or known WHO grade I meningiomas. Adjuvant SRS was an important option to enhance tumor control and survival in patients with residual or progressive tumors after resection.
引用
- Wei CZ, Niranjan A, Deng H, et al. The 35-Year Evolution of Stereotactic Radiosurgery for Meningiomas. Neurosurgery. 2025. PMID: 40844288. doi:10.1227/neu.0000000000003702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。